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First line drug treatment for hypertension and reductions in 
blood pressure according to age and ethnicity: cohort study in 
UK primary care
Sarah-Jo Sinnott,1 Ian J Douglas,1 Liam Smeeth,1 Elizabeth Williamson,2 Laurie A Tomlinson1
AbstrAct
Objective
To study whether treatment recommendations based 
on age and ethnicity according to United Kingdom (UK) 
clinical guidelines for hypertension translate to blood 




UK primary care, from 1 January 2007 to 31 December 
2017.
ParticiPants
New users of angiotensin converting enzyme 
inhibitors/angiotensin receptor blockers (ACEI/ARB), 
calcium channel blockers (CCB), and thiazides.
Main OutcOMe Measures
Change in systolic blood pressure in new users of 
ACEI/ARB versus CCB, stratified by age (< v ≥55) and 
ethnicity (black v non-black), from baseline to 12, 
26, and 52 week follow-up. Secondary analyses 
included comparisons of new users of CCB with those 
of thiazides. A negative outcome (herpes zoster) was 
used to detect residual confounding and a series of 
positive outcomes (expected drug effects) was used 
to determine whether the study design could identify 
expected associations.
results
During one year of follow-up, 87 440 new users 
of ACEI/ARB, 67 274 new users of CCB, and 
22 040 new users of thiazides were included 
(median 4 (interquartile range 2-6) blood pressure 
measurements per user). For non-black people who 
did not have diabetes and who were younger than 
55, CCB use was associated with a larger reduction 
in systolic blood pressure of 1.69 mm Hg (99% 
confidence interval −2.52 to −0.86) relative to ACEI/
ARB use at 12 weeks, and a reduction of 0.40 mm 
Hg (−0.98 to 0.18) in those aged 55 and older. In 
subgroup analyses using six finer age categories of 
non-black people who did not have diabetes, CCB 
use versus ACEI/ARB use was associated with a larger 
reduction in systolic blood pressure only in people 
aged 75 and older. Among people who did not have 
diabetes, systolic blood pressure decreased more 
with CCB use than with ACEI/ARB use in black people 
(reduction difference 2.15 mm Hg (−6.17 to 1.87)); 
the corresponding reduction difference was 0.98 mm 
Hg (−1.49 to −0.47) in non-black people.
cOnclusiOns
Similar reductions in blood pressure were found to 
be associated with new use of CCB as with new use 
of ACEI/ARB in non-black people who did not have 
diabetes, both in those who were aged younger than 
55 and those aged 55 and older. For black people 
without diabetes, CCB new use was associated with 
numerically greater reductions in blood pressure 
than ACEI/ARB compared with non-black people 
without diabetes, but the confidence intervals were 
overlapping for the two groups. These results suggest 
that the current UK algorithmic approach to first line 
antihypertensive treatment might not lead to greater 
reductions in blood pressure. Specific indications 
could be considered in treatment recommendations.
Introduction
High blood pressure, or hypertension, affects more 
than one in four adults globally and is a major 
modifiable risk factor for morbidity and mortality.1 
Internationally, guideline based approaches to 
pharmacotherapy for hypertension have been adopted 
to simplify clinical practice and improve blood pressure 
control.2-4 Although some evidence suggests that the 
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WhAt Is AlreAdy knoWn on thIs topIc
Current NICE recommendations for first line hypertension treatment are based on 
age, ethnicity, and diabetes
Excluding people with diabetes, calcium channel blockers (CCB) are 
recommended for those aged 55 and older and for people of black African or 
African-Caribbean family ethnicity (referred to here as black people to reflect 
diversity); angiotensin converting enzyme inhibitors or angiotensin receptor 
blockers (ACEI/ARB) are recommended for non-black people younger than 55
Since the current guidance was developed, the medical literature has evolved 
incrementally with more trials including older populations; meta-analysis of 
these new data indicate that the effectiveness of first line antihypertensive drugs 
does not differ by age (</>65); additionally, categorisations of ethnicity to guide 
clinical decision making have been questioned
It is not known whether recommended drug choices lead to greater reductions in 
blood pressure in current routine clinical care
WhAt thIs study Adds
In this propensity score matched cohort study excluding people with diabetes, 
initiation of either CCB or ACEI/ARB for hypertension was associated with similar 
reductions in blood pressure in people younger than 55 and those aged 55 
and older; subgroup analyses indicated that CCB was associated with greater 
reductions in blood pressure than ACEI/ARB only in those aged 75 and older
Reductions in blood pressure appeared to be numerically greater for black 
people initiating CCB versus ACEI/ARB than those blood pressure reductions 
in non-black people, but the confidence intervals overlapped between the two 
groups
The finding that ACEI/ARB and CCB are associated with similar reductions in 
blood pressure in those aged above and below 55 suggests that age might not 
be the best factor to determine drug choice; other characteristics, such as level 
of urinary protein loss, could favour choice of a specific class of drug
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effectiveness of drug treatment for hypertension does 
not differ across the general population,5 6 guideline 
recommendations hinge on the understanding 
that the effect of these drugs differs among specific 
subpopulations.
In the United Kingdom (UK), National Institute 
for Health and Care Excellence (NICE) guidelines 
recommend angiotensin converting enzyme inhibitors 
and angiotensin receptor blockers (ACEI/ARB) as first 
line treatment for hypertension in people younger than 
55, and calcium channel blockers (CCBs) for people 
without diabetes aged 55 and older, replacing CCB 
with thiazides for those with drug intolerance.2 The 
presence of an age based recommendation is unique 
among major international guidelines for hypertension 
treatment,3 4 and is based on differences in the activity 
of the renin-angiotensin system with age.7-9 Since this 
threshold was introduced in the first iteration of NICE 
hypertension guidance in 2004, the evidence base for 
hypertension treatment in older age, including the use 
and safety of ACEI/ARB drugs in older populations has 
evolved.10 11
Furthermore, in NICE guidelines, use of CCB or 
thiazides is recommended as first line treatment for 
black people of African or Caribbean ethnic origin 
(referred to in this article as black people to reflect 
diversity). The same drugs are recommended, after 
consideration of comorbidities, in international 
guidelines.2-4 The pathophysiology of hypertension in 
this population has been thought to differ importantly 
from people of white heritage; lower levels of renin 
result in a reduced response to hypertension drugs 
that block the renin-angiotensin system such as ACEI/
ARB.12 However, treatment recommendations based 
on historical categorisations of ethnicity have recently 
been criticised, because ethnicity can be considered a 
social construct rather than a biological one, and the 
proportion of people with mixed ethnic heritage has 
increased.13
Contemporary routine care is characterised by an 
increasingly older, more ethnically diverse and multi-
morbid population. For people initiating hypertension 
drugs, it is not known whether current age and 
ethnicity based treatment recommendations translate 
to greater blood pressure reductions in these settings.
The Quality and Outcomes Framework in the UK 
ensures that blood pressure is regularly measured 
and recorded in patients’ electronic health records in 
primary care.14 Along with complete information on 
drugs prescribed, these anonymised data are a rich and 
high quality resource for examining drug effectiveness.15 
Therefore, framing our questions around the current 
NICE algorithm for drug treatment of hypertension, we 
sought to determine whether initiation of CCB compared 
with ACEI/ARB led to differences in blood pressure 
reduction across age and ethnicity groups.
Methods
Data
We conducted a cohort study using the Clinical 
Practice Research Database (CPRD-GOLD) linked 
to Hospital Episodes Statistics. CPRD-GOLD is a 
nationally representative repository of prospectively 
collected, anonymised electronic health records from 
primary care in the UK, which has been extensively 
validated.16 It holds data on demographic information, 
health related behaviours, test results including blood 
pressure measurements, diagnoses, and prescriptions 
for more than 11 million people.16 The Hospital 
Episodes Statistics database records all hospital 
admissions for patients covered by the UK’s health 
service who receive treatment from either English 
NHS trusts or independent providers.17 Almost 60% of 
general practices included in CPRD-GOLD are linked 
to Hospital Episodes Statistics.16 We used linked data 
in this study to improve completeness of ethnicity 
recording.18
cohort entry
We identified new users of hypertension drugs 
(CCB, ACEI/ARB, and thiazides), defined as people 
who had a prescription for one of these drugs in the 
study period (1 January 2007 to 31 December 2017), 
with no previous use of these drugs in the preceding 
year. People entered the cohort (index date) on the 
date of the first prescription. People were eligible for 
inclusion from the latest of the following: study start 
date (1 January 2007), one year after general practice 
registration (to allow time for recording of covariates in 
the general practice record), the date when the general 
practices’ data recording processes were considered 
of adequate standard to be included in CPRD-GOLD, 
or the person’s 18th birthday. People remained in the 
cohort until the earliest of the following: end of the 
study period (31 December 2017), last data collection 
from the general practice, date of leaving the general 
practice, or death.
exclusion
We sought to study the association between first line 
drug treatment for hypertension and blood pressure 
solely in those individuals treated for hypertension. 
Therefore, we excluded people who initiated any 
of the study drugs without recorded blood pressure 
measurements in the year before cohort entry, 
and those whose blood pressure was at target or 
lower (<140/90 mm Hg, according to current NICE 
guidelines).2 We also excluded people who initiated 
more than one hypertension drug on the index date, 
as well as those with diabetes at baseline (because 
current NICE guidance recommends ACEI/ARB as 
first line hypertension treatment for all people with 
diabetes). Additionally, because ethnicity was a 
stratifying factor, we excluded people whose ethnicity 
was not determinable even after data linkage.
Outcomes
Our main analysis looked at the change in systolic 
blood pressure from baseline at 12 weeks, 26 weeks, 
and 52 weeks, and repeated this for diastolic blood 
pressure in a secondary analysis. We included two 
types of control analyses: a positive outcome control 
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and a negative outcome control.19 20 The rationale of 
positive outcome analyses is that they demonstrate 
whether known drug-outcome associations can be 
replicated in a dataset. If such associations cannot be 
found, this could indicate confounding or problems 
with the data or methods. We included the following 
positive outcomes: incidence of ankle swelling, 
gout, and angioedema, all outcomes that we would 
expect to occur with different incidence according to 
drug prescribed. We also included a negative control 
outcome; herpes zoster. Our rationale in this instance 
was that none of the hypertension drugs studied 
should be causally associated with an altered risk of 
herpes zoster. If an association was found between 
any drug group and herpes zoster, this would suggest 
confounding or bias.20
covariates
Baseline values of systolic and diastolic blood pressure 
were taken from CPRD-GOLD, measured on or as close 
as possible to the index date. Using a priori knowledge 
about factors that could influence treatment choice 
or response we defined multiple covariates: age, sex, 
smoking, alcohol use, body mass index, diabetes, 
myocardial infarction, stroke, heart failure, arrhythmia, 
peripheral vascular disease, cancer, depression, 
and chronic obstructive pulmonary disease. Chronic 
comorbidities were defined using records from 
information recorded in both CPRD-GOLD and Hospital 
Episodes Statistics using all available data. We 
determined whether each person had ever previously 
been prescribed statins, antiplatelet agents, proton 
pump inhibitors, insulin, and loop diuretics. To capture 
polypharmacy, we measured drug treatment use from 
multiple British National Formulary chapters in the 
year before index date. To capture health service use 
in the year before index date, we determined how often 
a person visited their general practice. To account for 
socioeconomic status, we used person level deprivation 
based on the 2010 English Index Multiple Deprivation 
scores, separated into five equal groups, using quintiles. 
We calculated baseline estimated glomerular filtration 
rate from the most recent creatinine value recorded in 
CPRD-GOLD within one year before index date using 
the CKD-EPI (Chronic Kidney Disease Epidemiology 
Collaboration) equation. This variable was categorised 
into five groups: no CKD (estimated glomerular filtration 
rate ≥60), stage 3a (45-59), stage 3b (30-44), stage 4 
(15-29), and stage 5 (<15).
To retain power in our main analysis, we imputed 
missing data under the missing-at-random assumption. 
Data for renal function were approximately 30% 
missing; our previous work has shown that people 
without recorded renal function have similar health 
outcomes to those with normal renal function after 
adjusting for covariates such as age, diabetes, and 
vascular disease.21 Data for other variables (smoking, 
alcohol, and body mass index) were approximately 
5% missing. The imputation model included all 
explanatory variables listed above, including the 
outcome variable (first measurement of systolic 
and diastolic blood pressure during follow-up). We 
conducted diagnostics using the midiagplots function 
in Stata.22 We created five imputed datasets and 
combined treatment effects across these to obtain one 
overall estimate in each of our analyses.23
analysis
Reflecting current NICE guidance,2 we sought to 
answer two specific research questions in relation to 
blood pressure reduction. Firstly, in non-black people 
who do not have diabetes, is CCB versus ACEI/ARB for 
hypertension associated with different reductions in 
blood pressure in those younger than 55 versus those 
aged 55 and older? And secondly, in people who do 
not have diabetes, are CCB associated with different 
reductions in blood pressure than ACEI/ARB by black 
or non-black ethnicity? We also compared use of 
thiazides versus CCB to give insight into drugs that are 
recommended as alternative choices.2
Therefore, among new users of ACEI/ARB or CCB, 
within each of four groups defined by age (</≥55) 
and ethnicity (black/non-black), we estimated the 
propensity to be prescribed CCB versus ACEI/ARB using 
a logistic regression model including all the covariates 
listed above, except for diastolic blood pressure. Then, 
within each group, we matched one CCB user to one 
ACEI/ARB user on their propensity score within a 
caliper of 1%. We used linear mixed models to model 
change in systolic blood pressure with a random 
intercept for each person and fixed effects for exposure 
drug, using splines over time to allow the effects of 
exposure to vary flexibly over time. The fitted model 
was used to predict the blood pressure value at each 
follow-up (at 12 weeks, 26 weeks, and 52 weeks), so 
did not require patients to have measurements taken 
at those particular time points. In this way, the model 
could accommodate unbalanced data.24 Furthermore, 
this type of model can accommodate correlations 
within each person for longitudinal blood pressure 
measurements. The same analysis was used to compare 
thiazides versus CCB.
We used Cox proportional hazards models for the 
control outcomes within each of the propensity score 
matched groups defined above. For the gout and ankle 
swelling outcome models, we observed violation of the 
proportional hazards assumption. For these outcomes, 
we also modelled time specific hazard ratios. To reduce 
the risk of type I error with multiple testing, we defined 
a priori that we would report 99% confidence intervals.
subgroup and sensitivity analyses
To look more closely at CCB versus ACEI/ARB and 
thiazide versus CCB in reducing systolic blood pressure 
according to age in a non-black population that did not 
have diabetes, we used finer age categories for group 
specific analyses (age <55, 55 to <60, 60 to <65, 65 to 
<70, 70 to <75, and ≥75) and propensity score matched 
within each age group. We studied reductions in 
blood pressure associated with thiazide-like diuretics 
(indapamide and chlortalidone) versus CCB and also 
older thiazide agents versus CCB.
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Our main analysis represented an intention-to-
treat approach, so we also carried out an as-treated 
analysis whereby we censored follow-up blood 
pressure data if participants switched to or added 
another hypertension drug or discontinued their 
drug, defined as no repeat prescription within 90 
days of previous prescription. This analysis aimed 
to examine the results for time spent on the drug 
initiated rather than the duration of follow-up that 
could include other drugs or no drugs. We carried out 
a complete case analysis to explore the impact of our 
multiple imputation approach. Finally, as a post hoc 
addition, we repeated our main analysis with 95% 
confidence intervals.
Patient and public involvement
No patients were involved in setting the research 
question or the outcome measures, nor were 
they involved in developing plans for design or 
implementation of the study. No patients were asked to 
advise on interpretation or writing up of results.
results
From more than 1 million users of hypertension drugs 
between 2007 and 2017, we identified 87 440 new 
users of ACEI/ARB, 67 274 new users of CCB, and 
22 040 new users of thiazides (fig 1). People taking 
thiazides were more likely to be female and were older 
than users of other hypertension drugs, while people 
taking ACEI/ARB group had a higher prevalence of 
myocardial infarction, heart failure, and diabetes (table 
1). People without a blood pressure measurement 
during one year of follow-up were dropped from the 
blood pressure analysis (n=10 840). Demographics 
and comorbidity profiles were similar between those 
with and without blood pressure measurements 
(appendix 1).
For each drug comparison, we matched people on 
propensity score and achieved good balance on all 
covariates within age and ethnicity groups (appendices 
2 and 3). Within the matched group of people with black 
ethnicity for each drug comparison, there was a 1 mm 
Hg difference in systolic blood pressure at baseline. A 
median of four (interquartile range 2-6) blood pressure 
measurements per person were available during the 
one year follow-up.
change in systolic blood pressure for ccb versus 
acei/arb use by age
In people younger than 55, systolic blood pressure 
changed from 162.8 mm Hg to 140.7 mm Hg at 12 
weeks in new users of CCB, compared with a change 
from 162.7 mm Hg to 142.2 mm Hg in new users of 
ACEI/ARB. In relative terms, for people younger than 
55, CCB use was associated with a reduction in systolic 
blood pressure of 1.69 mm Hg (99% confidence 
interval −2.52 to −0.86) more than ACEI/ARB use (table 
2). In those aged 55 and older, systolic blood pressure 
changed from 163.8 mm Hg to 143.2 mm Hg at 12 
weeks in new users of CCB, compared with a change 
from 164.6 mm Hg to 144.6 mm Hg in new users of 
ACEI/ARB (fig 2; table 2; relative difference −0.40 mm 
Hg (−0.98 to 0.18) in favour of CCB). Over one year’s 
follow-up, no difference was observed for reductions in 
systolic blood pressure associated with CCB and ACEI/
ARB use in either age group (table 2 and fig 2).
change in systolic blood pressure for ccb versus 
acei/arb use by ethnicity
Among black people, systolic blood pressure changed 
from 156.0 mm Hg to 140.1 mm Hg at 12 weeks in 
new users of CCB, compared with a change from 
158.4 mm Hg to 144.1 mm Hg in new users of ACEI/
ARB. In relative terms, for black people, CCB use was 
associated with a reduction in systolic blood pressure 
of 2.15 mm Hg (99% confidence interval −6.17 to 1.87) 
more than ACEI/ARB use (table 2). Among non-black 
people, systolic blood pressure changed from 163. 
6 mm Hg to 143.5 mm Hg at 12 weeks in new users 
of CCB compared with a change from 163.7 mm Hg to 
143.8 mm Hg in new users of ACEI/ARB (fig 2; relative 
reduction of 0.98 mm Hg (99% confidence interval 
−1.49 to −0.47) among CCB initiators). Over one year’s 
All users of hypertension drugs in CPRD eligible for HES
linkage and eligible for study inclusion, 2007-17
People who initiate more than


















615 740   ACE/ARB 454 499   CCB 310 552   Thiazide
New users
120 722   ACE/ARB 91 432   CCB 31 473   Thiazide
Single drug new users
114 463   ACE/ARB 85 346   CCB 29 053   Thiazide
Number of new users with BP readings in year before cohort entry
106 948   ACE/ARB 77 816   CCB 29 956  Thiazide
Number of new users with high BP readings in year before cohort entry
87 440   ACE/ARB 67 274   CCB 22 040   Thiazide
116 601   ACE/ARB 87 934   CCB 29 059   Thiazide
Fig 1 | study flowchart. ccb=calcium channel blockers; acei=angiotensin converting 
enzyme inhibitors; arb=angiotensin receptor blockers; cPrD-gOlD=clinical Practice 
research Database; Hes=Hospital episodes statistics; bP=blood pressure
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acei/arb (n=87 440) ccb (n=67 274) thiazides (n=22 040)
sex
Female 37 158 (42.5) 33 506 (49.8) 14 277 (64.8)
age
<50 29 079 (33.3) 9204 (13.7) 2372 (10.8)
50-54 15 178 (17.4) 5377 (8.0) 1341 (6.1)
55-59 11 190 (12.8) 9522 (14.2) 2302 (10.4)
60-64 10 215 (11.7) 11 686 (17.4) 3394 (15.4)
65-69 7795 (8.9) 10 746 (16.0) 3205 (14.5)
70-74 5763 (6.6) 8421 (12.5) 3139 (14.2)
≥75 8220 (9.4) 12 318 (18.3) 6287 (28.5)
blood pressure (mm Hg; mean (standard deviation))
Systolic 160.2 (16.6) 165.8 (18.1) 164.3 (17.2)
Diastolic 94.8 (11.4) 93.8 (12.1) 91.5 (11.2)
ethnicity
White 73 247 (83.8) 55 477 (82.5) 19 253 (87.4)
South Asian 2949 (3.4) 1684 (2.5) 372 (1.7)
Black 914 (1.1) 3096 (4.6) 389 (1.8)
Other/mixed/unknown 3214 (3.7) 2394 (3.6) 707 (3.2)
Missing data 7116 (8.1) 4623 (6.9) 1319 (6.0)
index Multiple Deprivation scores (separated into five equal groups using quintiles)
Group 1 (least deprived) 20 174 (23.1) 15 540 (23.1) 40 491 (22.9)
Group 2 20 481 (23.4) 15 822 (23.5) 41 637 (23.6)
Group 3 17 616 (20.2) 13 457 (20.0) 35 634 (20.2)
Group 4 16 301 (18.6) 12 795 (19.0) 33 233 (18.8)
Group 5 (most deprived) 12 810 (14.7) 9,631 (14.3) 25 655 (14.5)
Missing data 58 (0.1) 29 (0.04) 17 (0.1)
body mass index
Underweight, <18.5 646 (0.7) 863 (1.3) 361 (1.6)
Healthy weight, 18.5-24.9 17 317 (19.8) 17609 (26.2) 6152 (27.9)
Overweight, 25-29.9 31 198 (35.7) 25 329 (37.7) 7755 (35.2)
Obesity, ≥30 35 119 (40.2) 20 498 (30.5) 6841 (31.0)
Missing data 3160 (3.6) 2975 (4.4) 931 (4.2)
smoking
Non-smoker 29 956 (34.3) 23 302 (34.6) 7984 (36.2)
Current smoker 18 183 (20.8) 12 632 (18.8) 3830 (17.4)
Ex-smoker 39 206 (44.8) 31 168 (46.3) 10 171 (46.1)
Missing data 95 (0.1) 172 (0.3) 55 (0.2)
alcohol
Non-drinker 7929 (9.1) 7060 (10.5) 2663 (12.1)
Current drinker 67 932 (77.7) 50 627 (75.3) 16 236 (73.7)
Ex-drinker 7332 (8.4) 6197 (9.2) 2093 (9.5)
Missing data 4247 (4.9) 3390 (5.0) 1048 (4.8)
comorbidities
Myocardial infarction 2489 (2.8) 449 (0.7) 158 (0.7)
Stroke 2671 (3.1) 2199 (3.3) 785 (3.6)
Heart failure 1122 (1.3) 294 (0.4) 114 (0.5)
Peripheral vascular disease 2427 (2.8) 2872 (4.3) 896 (4.1)
Diabetes 15 095 (17.3) 4289 (6.4) 975 (4.4)
Depression 6677 (7.6) 4756 (7.1) 1547 (7.0)
Chronic obstructive pulmonary disease 3141 (3.6) 3748 (5.6) 1250 (5.7)
Cancer 6455 (7.4) 7822 (11.6) 2729 (12.4)
Herpes zoster 4872 (5.6) 5067 (7.5) 1939 (8.8)
Gout 4365 (5.0) 3207 (4.8) 645 (2.9)
Angioedema 61 (0.1) 67 (0.1) 5 (0.0)
chronic kidney disease
No chronic kidney disease 57 963 (66.3) 37 990 (56.5) 11 824 (53.6)
Stage 3a 6132 (7.0) 4726 (7.0) 2126 (9.6)
Stage 3b 1541 (1.8) 999 (1.5) 393 (1.8)
Stage 4 218 (0.2) 251 (0.4) 44 (0.2)
Stage 5 28 (0.0) 96 (0.1) —
Missing data 21 558 (24.7) 23 212 (34.5) 7651 (34.7)
Drug treatments
Anti-platelet agents 11 868 (13.6) 9590 (14.3) 3699 (16.8)
Statins 19 769 (22.6) 13 740 (20.4) 4232 (19.2)
table 1 | Descriptive characteristics for new users of angiotensin converting enzyme inhibitors/angiotensin receptor 
blockers (acei/arb), calcium channel blockers (ccb), and thiazides at baseline. Data are number (%) of users unless 
stated otherwise
(Continued)
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follow-up, no difference in reductions of systolic blood 
pressure was seen between CCB and ACEI/ARB use for 
either non-black or black people (table 2 and fig 2). We 
found results of similar magnitude and direction for 
diastolic blood pressure (appendices 4 and 5).
change in systolic blood pressure for thiazide use 
versus ccb use by age and ethnicity
For people aged 55 and older, new use of CCB were 
associated with greater reductions in systolic blood 
pressure than new use of thiazides at 12 and 26 
weeks. However, the reductions observed were similar 
to those for people younger than 55 years, indicated 
by overlapping confidence intervals. Similarly, over-
lapping confidence intervals for blood pressure 
reductions in each of the ethnicity groups indicated no 
evidence for a difference for thiazide versus CCB use 
in black and non-black people (table 2 and fig 3). We 
observed similar results for diastolic blood pressure 
(appendices 4 and 5).
control analyses
The incidence of drug specific side effects was as 
expected for each drug comparison; we found a higher 
incidence of ankle swelling for new users of CCB 
than for new users of ACEI/ARB (hazard ratio 1.77, 
99% confidence interval 1.61 to 1.94), and a lower 
incidence of ankle swelling for new users of thiazides 
than for new users of CCB (0.69, 0.61 to 0.78; fig 4). 
We saw no evidence indicating that the incidence of 
herpes zoster differed between drug groups in either 
drug comparison (fig 4). Appendix 7 presents negative 
and positive control analyses as well as time specific 
hazard ratios for each study group.
sensitivity analyses
Across all age categories, among non-black people 
who did not have diabetes, we found that new use of 
CCB was associated with larger reductions in systolic 
blood pressure relative to new use of ACEI/ARB only in 
those aged 75 and older (12 week change −3.0 mm Hg 
(99% confidence interval −4.05 to −1.93), 26 weeks 
change −1.90 mm Hg (−3.03 to −0.77), 52 weeks 
change −1.86 mm Hg (−3.08 to −0.64); fig 5). CCB were 
associated with larger reductions than thiazides in all 
age categories at 12 weeks, but the difference between 
the drugs became negligible with increasing time 
(fig 5).
In the whole cohort matched by propensity score, 
we found that thiazide-like drugs (indapamide and 
chlortalidone) were of similar effectiveness to CCB in 
terms of lowering systolic blood pressure, and that CCB 
were more effective than older thiazide drugs (appendix 
8). Our as-treated analysis provided results that were 
table 2 | Difference in systolic blood pressure since initiation of hypertension drug treatment for study drug 
comparisons (ccb v acei/arb; thiazide v ccb), by study group. Data are mm Hg (99% confidence interval)
study group* no
Follow-up period 
12 weeks 26 weeks 52 weeks
Difference in change of systolic blood pressure from baseline between ccb use and acei/arb use†
Age <55 20 964 −1.69 (−2.52 to −0.86) −0.48 (−1.47 to 0.51) −0.53 (−1.96 to 0.91)
Age ≥55 58 396 −0.40 (−0.98 to 0.18) 0.63 (0.06 to 1.21) 0.85 (−0.11 to 1.81)
Non-black 73 726 −0.98 (−1.49 to −0.47) 0.11 (−0.42 to 0.64) 0.08 (−0.81 to 0.96)
Black 894 −2.15 (−6.17 to 1.87) 0.55 (−3.39 to 4.49) 2.28 (−5.36 to 9.92)
Difference in change of systolic blood pressure from baseline between thiazide use and ccb use‡
Age <55 5724 1.51 (−0.03 to 3.06) 0.07 (−1.70 to 1.83) 0.34 (−2.39 to 3.07)
Age ≥55 32 464 2.16 (1.35 to 2.96) 1.43 (0.56 to 2.31) 0.17 (−0.95 to 1.30)
Non-black 35 876 2.10 (1.37 to 2.82) 1.19 (0.40 to 2.0) 0.32 (−0.74 to 1.38)
Black 648 −0.28 (−5.69 to 5.14) −1.75 (−6.98 to 3.48) 2.01 (−5.46 to 9.47)
CCB=calcium channel blockers; ACEI=angiotensin converting enzyme inhibitors; ARB=angiotensin receptor blockers. All analyses are 1:1 matched by 
propensity score within each group. The total number for each stratum consists of half CCB and half ACEI/ARB (or half thiazide and half CCB). Appendix 6 
shows changes in systolic blood pressure with 95% confidence intervals.
*Groups did not include people with diabetes.
†For the CCB v ACEI/ARB comparison, a negative result means that CCB use resulted in larger reductions in systolic blood pressure than ACEI/ARB use; a 
positive result indicates that ACEI/ARB use resulted in larger reductions in systolic blood pressure than CCB use. 
‡For the thiazide v CCB comparison, a negative result means thiazide use resulted in larger reductions in systolic blood pressure than CCB use; a positive 
result indicates that CCB use produced larger reductions in systolic blood pressure than thiazide use.
acei/arb (n=87 440) ccb (n=67 274) thiazides (n=22 040)
Proton pump inhibitors 29 775 (34.1) 26 374 (39.2) 8139 (36.9)
Insulin 2352 (2.7) 422 (0.6) 84 (0.4)
Loop diuretics 3109 (3.6) 2813 (4.2) 1607 (7.3)
Non-steroidal anti-inflammatory drugs 56 108 (64.2) 44 292 (65.8) 14 663 (66.5)
no of primary care consultations
<5 22 829 (26.1) 17 330 (25.8) 5563 (25.2)
5-9 28 577 (32.7) 20 855 (31.0) 7237 (32.8)
10-14 16 106 (18.4) 12 243 (18.2) 4121 (18.7)
15-19 8091 (9.3) 6591 (9.8) 2081 (9.4)
≥20 11 837 (13.5) 10 255 (15.2) 3038 (13.8)
Missing data 0 0 0
table 1 | continued
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broadly similar to the main analysis. The numerical 
reduction in blood pressure was greater among black 
people commencing CCB than those commencing 
ACEI/ARB (−3.65 mm Hg, 99% confidence interval 
−7.99 to 0.70), compared with the corresponding 
numerical reduction observed in non-black people 
(−0.35 mm Hg, −0.94 to 0.24). However, the 99% 
confidence intervals were overlapping for both groups, 
indicating no strong evidence for a difference, similar 
to the main analysis (appendix 9). The complete case 




This propensity score matched cohort study included 
more than 150 000 people with hypertension 
in routine primary care in the UK. We found no 
evidence to support a difference in the blood pressure 
reductions observed for CCB versus ACEI/ARB among 
non-black people who did not have diabetes and who 
were aged above and below 55. In subgroup analyses, 
however, we found that CCB were associated with 
larger reductions in blood pressure than ACEI/ARB in 
people older than 75. Among people who did not have 
diabetes, our results suggested a numerically greater 
reduction in systolic blood pressure for CCB versus 
ACEI/ARB new use among black people compared 
with non-black people, but the confidence intervals 
for the reductions overlapped between the two groups 
indicating no strong evidence for a difference.
strengths and limitations
It is possible that people initiating hypertension drugs 
other than first line options suggested by current 
guidance were prescribed them for other indications. 
Despite good balance on baseline comorbidities 
in matched cohorts, residual confounding caused 
by unrecorded heart failure and kidney disease 
could have attenuated the blood pressure response 
to treatment. However, we endeavoured to reduce 
confounding by indication by including only people 
with hypertension; undertaking our analyses only in 
people who did not have diabetes; and matching by 
propensity score on multiple factors, inclusive of heart 
failure. This last approach achieved highly balanced 
cohorts for each drug comparison within each group. 
Furthermore, we used multiple strategies to help detect 
bias in our matched cohorts; our negative outcome 
analysis demonstrated no increased risk of herpes 
zoster in any drug group.20 Additionally, our positive 
outcome analyses showed that our data and methods 
were sensitive to drug effects anticipated to be causally 
associated with specific hypertension drugs. 
Our results related to ethnicity have wide margins 
of uncertainty, which could have occurred for several 
reasons. Firstly, we compared changes in blood 
pressure between black and non-black people, 
consistent with current UK guidance.2 Much of the 
original clinical research that informs this guidance 
compared people with an African or Caribbean ethnic 
origin versus people classified as white. If people of 
non-black and non-white ethnicity in our study had 
intermediate responses to the hypertension drug 
classes, their inclusion in the non-black group could 
have contributed to the overlapping confidence 
intervals observed for non-black and black people. 
Secondly, we had small numbers of black people 
initiating ACEI/ARB as a first line treatment for 
hypertension, suggesting that current NICE guidance 
is closely adhered to. Thirdly, the uncertainty we 
observed could have reflected the wide variation in 
the activity of the renin-angiotensin system across all 
ethnic groups.
Our outcomes relied on measurements of blood 
pressure at clinics because these measurements are 
recommended by NICE to monitor hypertension in 
primary care and to guide treatment decisions, except 
for patients suspected of white coat hypertension or 
resistant hypertension, in whom ambulatory or home 
monitoring is recommended.2 Therefore, the blood 
pressure measurements used in this study reflect the 
provision of care as it occurs routinely. Furthermore, 
we do not expect that any one method of blood pressure 
measurement was more or less concentrated in any one 
drug group, thus removing the risk of measurement 
bias. Our study did not look at the issue of adherence to 
hypertension drugs, although our as-treated analysis 
did censor individuals if they discontinued their index 
drug.
CCB v ACEI/ARB: achieved systolic blood pressure since
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Fig 2 | achieved systolic blood pressures from baseline after new use of calcium 
channel blockers (ccb) versus new use of angiotensin converting enzyme inhibitors/
angiotensin receptor blockers (acei/arb) for hypertension in study groups, by study 
follow-up
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comparison with the literature and other studies
NICE guidelines recommend ACEI/ARB as the first line 
treatment for hypertension for those younger than 55.2 
This age threshold, currently absent in international 
guidelines, is based on the idea that hypertension 
in younger people is more commonly characterised 
by high renin levels.7 8 The age cut-off point in NICE 
guidelines is supported by studies limited by small 
sample size (<60 people)7 8 and short follow-up periods 
(<6 weeks),7 8 restricted to men9 and geographical 
location,7 and including unpublished data.25 To 
support drug recommendations in those aged 55 years 
and older, three trials are cited in the NICE guidance 
although none show clear effect modification by age 
(usually categorised as age <60/>60 or <65/>65) for 
any included clinical outcome.26-28 Our age stratified 
results are in line with a meta-analysis of 31 trials 
including more than 190 000 patients, which 
showed no difference in blood pressure reduction or 
cardiovascular events for any hypertension drug class 
between patients aged younger or older than 65.29 
Our result of no difference in effectiveness between 
CCB and ACEI/ARB in new users aged 55 and older 
also accords with the results of a randomised study 
that examined effectiveness of first line treatment for 
lowering blood pressure between people aged younger 
than 55 and those aged 55 and older.30
Since first including 55 years as the age threshold 
in NICE guidance (CG18) in 2004, the literature has 
evolved to capture older populations with subgroup 
analyses based on older ages (comparison threshold 
at age 75) or subgroups defined by frailty.10 11 In 
our subgroup analyses, greater reductions in blood 
pressure were found for CCB versus ACEI/ARB use 
only in those aged 75 and older. This finding could 
reflect an increased prevalence of isolated systolic 
hypertension in this subgroup (57% for age ≥75 v 
CCB v ACEI/ARB
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Fig 4 | Positive and negative outcomes for entire study population (excluding people with diabetes) in hypertension drug comparison groups 
matched by propensity score. Positive and negative outcomes for each group level comparison are presented in appendix 7. ccb=calcium channel 
blockers; acei=angiotensin converting enzyme inhibitors; arb=angiotensin receptor blockers
Thiazides v CCB: achieved systolic blood pressure since
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Fig 3 | achieved systolic blood pressures from baseline after new use of thiazide versus 
calcium channel blockers (ccb) for hypertension in study groups, by study follow-up
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40% for age ≥55 in our data), for which CCB might 
be more effective.31 32 Although our results suggested 
no clear benefit in blood pressure reductions for CCB 
compared with ACEI/ARB in people aged 55 and older, 
the range of side effects might be as important as 
drug effectiveness in considering which hypertension 
drug class to prescribe. This decision is particularly 
important in older patients whose higher prevalence 
of comorbidities such as advanced chronic kidney 
disease could favour the use of CCB.
International guidelines for hypertension are 
similar to NICE guidelines in that ethnicity is a major 
consideration in the choice of a first line hypertension 
drug, although they do not use the algorithmic approach 
of UK guidance. Ethnicity based recommendations 
are supported by strong evidence from the ALLHAT 
randomised clinical trial, which showed use of 
thiazides or CCB was more effective than ACEI/ARB at 
lowering blood pressure in black people.28 We have 
suggested above several reasons why our results might 
differ from established clinical evidence. However, the 
value of making clinical decisions based on ethnicity is 
increasingly questioned given the growing proportion 
of people who classify themselves as multiethnic or 
of mixed heritage.13 Furthermore, our understanding 
of interactions between genetic and environmen-
tal factors in the development of hypertension is 
improving.33 Thus, the value of using categorisations 
of ethnicity as a proxy predictor for drug response is 
uncertain in current society, although is likely to be 
informed by ongoing research.34
conclusion
In conclusion, we observed reductions in blood 
pressure for CCB that were similar in magnitude to 
those for ACEI/ARB in people aged above and below 
55. This finding suggests that some people aged 55 
and older who are currently offered CCB, but have 
indications for renin-angiotensin blockade such as 
proteinuria, could be missing the therapeutic benefits 
of ACEI/ARB. We found no evidence that CCB new use 
was associated with larger reductions in blood pressure 
than ACEI/ARB new use among black people versus 
other ethnic groups, although power was limited and 
uncertainty existed in the estimate. Our results suggest 
that the algorithm for choice of pharmacotherapy in 
UK NICE guidance could be simplified. Moving towards 
a choice of any of the three major hypertension drug 
classes with suggested compelling indications for their 
use would align the UK with international guidance, in 
particular with regard to age.
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Fig 5 | Difference in systolic blood pressure (sbP) across age groups for calcium channel 
blockers (ccb) versus angiotensin converting enzyme inhibitors/angiotensin receptor 
blockers (acei/arb) and for thiazides versus ccb. bars=99% confidence intervals
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